Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

@article{Frmond2016EfficacyOT,
  title={Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.},
  author={Marie-Louise Fr{\'e}mond and Mathieu P Rodero and Nadia Jeremiah and Alexandre Belot and {\'E}ric Jeziorski and Darragh Duffy and D Bessis and Guilhem Cros and Gillian I Rice and Bruno Charbit and Anne Hulin and Nihel Khoudour and Consuelo Modesto Caballero and Christine Bodemer and Monique Fabr{\`e} and L. Berteloot and Muriel le Bourgeois and Phillipe Reix and Thierry Walzer and Despina Moshous and St{\'e}phane Blanche and Alain Fischer and Brigitte Bader-Meunier and Fr{\'e}d{\'e}ric Rieux-Laucat and Yanick J Crow and B{\'e}n{\'e}dicte Neven},
  journal={The Journal of allergy and clinical immunology},
  year={2016},
  volume={138 6},
  pages={
          1752-1755
        }
}
Marie-Louise Frémond, MD, Mathieu Paul Rodero, PhD, Nadia Jeremiah, PhD, Alexandre Belot, MD, PhD, Eric Jeziorski, MD, Darragh Duffy, PhD, Didier Bessis, MD, Guilhem Cros, MD, Gillian I. Rice, PhD, Bruno Charbit, MSc, Anne Hulin, PharmD, PhD, Nihel Khoudour, MD, Consuelo Modesto Caballero, MD, Christine Bodemer, MD, PhD, Monique Fabre, MD, Laureline Berteloot, MD, Muriel Le Bourgeois, MD, Philippe Reix, MD, Thierry Walzer, PhD, Despina Moshous, MD, PhD, Stéphane Blanche, MD, PhD, Alain Fischer… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
10 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…